Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
J A Rowan
Dr J A Rowan, Auckland City Hospital, Auckland, New Zealand; email@example.com
randomised controlled trial (Metformin in Gestational Diabetes [MiG] Trial).
10 obstetric hospitals in New Zealand and Australia.
751 women 18–45 years of age (mean age 33 y) who were 20–33-weeks pregnant with a single healthy fetus and had gestational diabetes requiring medical treatment (fasting blood glucose >97.2 mg/dl [5.4 mmol/l] or 2-h postprandial blood glucose >120.6 mg/dl [6.7 mmol/l] on >1 occasion after lifestyle intervention). Exclusion criteria included pre-pregnancy diabetes, hypertensive disorders, and ruptured membranes.
metformin, 500 mg once or twice daily, increased to a maximum of 2500 mg/day, with insulin added as needed (n = 373) or insulin administered according to each centre’s standard practice (n = 378). Target concentrations were <99 mg/dl (5.5 mmol/l) for fasting and <126 mg/dl (7.0 mmol/l) for 2-h postprandial blood glucose (or less).
composite neonatal outcome (hypoglycaemia, respiratory distress, need for phototherapy, birth trauma, 5-min Apgar score <7, or preterm birth) and maternal hypertensive complications and weight gain. The study had 80% power to detect an absolute difference of 10% in the primary composite …
Source of funding: Auckland Medical Research Foundation; National Women’s Evelyn Bond Charitable Trust; Health Research Council of New Zealand; National Health and Medical Research Council of Australia.